Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 6/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920558 | 0.83 | CYP3A4 (0.45) | CYP3A4TGFBR1METAP2GSK3BDYRK1A | |
| SCHEMBL12059505 | 0.83 | CYP3A4 (0.47) | CYP3A4TGFBR1METAP2GSK3BDYRK1A | |
| SCHEMBL6922064 | 0.83 | CYP3A4 (0.46) | CYP3A4TGFBR1METAP2GSK3BDYRK1A | |
| SCHEMBL6921554 | 0.82 | CYP3A4 (0.46) | CYP3A4TGFBR1METAP2GSK3BDYRK1A | |
| SCHEMBL2053242 | 0.80 | POLB (0.49) | ABL1 | |
| SCHEMBL6921561 | 0.79 | CYP3A4 (0.46) | CYP3A4TGFBR1METAP2GSK3BDYRK1A | |
| SCHEMBL6922231 | 0.77 | CACNA2D1 (0.39) | — | |
| SCHEMBL12059110 | 0.77 | CYP3A4 (0.46) | CYP3A4TGFBR1METAP2DHODHBRD4 | |
| SCHEMBL6922215 | 0.77 | TGFBR1 (0.43) | CYP3A4TGFBR1METAP2NPY5RDHODH | |
| SCHEMBL6922480 | 0.76 | ACHE (0.44) | CYP3A4TGFBR1METAP2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | CYP3A4 4447/4885TGFBR1 3543/4885METAP2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.